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Sir
The paper by Henriksson and colleagues has methodologic varia-
tions leading to important drawbacks and therefore is of limited
value in answering the question of whether immunotherapy
improves survival.
The authors state that they compare ‘one of the present (and
presumed best) treatments, interleukin-2, a-interferon and tamox-
ifen, with a control arm of tamoxifen only’ and that they use ‘a
schedule reported previously by Atzpodien and colleagues’
(Atzpodien et al, 1990). There is a dramatic and probably impor-
tant difference in the doses of interleukin-2 (IL-2) and a-interferon
(IFN-a) between the two protocols. For example, Atzpodien and
colleagues gave a total of 36 million IU IL-2/day for 2 days to start
their protocol, whereas the Swedish study protocol called for 9
million IU IL-2/day. In general, doses used in the Swedish
protocol are 50% of the cited schedule or less. In addition, the
authors state that only 40 patients of the 65 patients in the treat-
ment arm received 75% or more of the intended dose; 25 of the
patients received less than 75% of the intended dose and five of
them less than 25% of the intended dose. No data are available
how many patients received the intended dose or at least 90% of it.
It cannot be expected that cytokine effects are completely dose-
independent as it seems to be assumed by the authors. The treat-
ment schedule of this protocol constitutes a very different schedule
from the one they cite, and substantial dose reduction might
decrease therapeutic effects substantially. This treatment variant
could be inefficient in improving survival. However, it has to be
questioned even whether this is answered by the study. Relevant
patient information is missing. No information is available whether
only patients with proven progressive disease were included in the
study. Generally accepted and well-known risk factors on survival
published by Elson such as weight loss, ECOG, or diagnostic time
interval (Elson et al, 1988), are not used to stratify the study popu-
lation of the seven institutions involved in treating the patients.
Instead the authors use laboratory data and an evaluation of specific
time frames. However, the laboratory data (haemoglobin, platelets,
white-cell count, creatinine and albumin) and the time frame
analysis have not been shown to substitute for Elson’s risk factors
in determining survival as assumed by the authors.
Important methodological issues, such as significant dose reduction,
are not stated in the Abstract or Methods section and are not
discussed. Treatment protocol is given as a legend only and recog-
nition of these important dose modifications in the Abstract is not
possible and in the paper needs detailed search. The paper contains
little information on the effect of IL-2, IFN-a treatment on
survival in progressive metastatic renal cell cancer. A major
concern of the authors was toxicity of treatment. In fact, they state
that ‘immunological manipulation is associated with toxicity, at
least during the treatment period’. This is true only for systemic
applications. Local applications of cytokines can have
immunomodulatory effects and no toxicity at all, as we have
shown previously (Huland and Huland, 1989). Inhaled, local IL-2
has also been used with only moderate toxicity by our group
(Huland et al 1992, 1997) resulting in stable quality of life during
mean 13, 4 months of treatment (Heinzer et al, 1999). Survival
data in patients treated with inhalation of IL-2 are promising,
compared to risk factors on survival, published by Elson. Local
treatment schedules without toxicity might allow efficient thera-
pies to be found without the limitations of dose-dependent
systemic toxicity.
E Huland and H Heinzer
Department of Urology, University Hospital Eppendorf,
Martinistr. 52, 22046 Hamburg, Germany
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Survival in renal cell carcinoma: a randomized
evaluation of tamoxifen vs interleukin-2, a-interferon
(leucocytic) and tamoxifen — reply
Sir
Although the comments by Drs Huland and Heinzer regarding our
study comparing tamoxifen versus interleukin-2, a-interferon
(leucocyte) and tamoxifen in general terms are acknowledged, it is
obvious that there is a need for clarification.
We are well aware that our study could be questioned forLetters to the Editor 247
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various reasons, as directly and straightforwardly outlined in the
discussion of the article. Nevertheless, we are somewhat aston-
ished by the reason for the critical comments by Drs Huland and
Heinzer, related for the most part to the fact that they only rely
their discussion on non-randomized studies including selected
population of patients. In fact, we lack references to well
controlled studies. An obvious shortcoming of most of the previ-
ously published studies within the field of immunotherapy is the
conclusion that the response rate was superior to ‘historic
controls’, although these trials were not randomized, and did not
use case-matched controls (Philip et al, 1993).
It has to be emphasized that our study investigated the general
applicability of the therapy concept in the management of patients
with good performance status (WHO 0–2). Even if it is a possibility
that the doses delivered to the patients are lower than proposed to
be optimal by Huland and Heinzer, it was clear that in our hands
many of the patients (note patients with high performance status)
required dose-reduction to be able to manage the treatment at all.
The toxicity encountered was in accordance with earlier reported,
and included a substantial number of patients with grade 3 and 4
toxicity. Thus, the adverse effects seen deteriorated quality of life in
a significant manner of the patients treated with immunotherapy.
Publication is also underway for the final evaluation of quality of
life for the whole study. This gives at least a further support that the
doses used were of clinical significance, i.e. the toxicity was
substantial. There exist no conclusive studies that clearly demon-
strate a dose–response relationship for cytokines in the clinical situ-
ation. Most likely, there is a quite different dose–response
correlation for cytokines (‘bell-shaped’) compared to chemothera-
peutics. Thus, it is not clear that ‘more is better’.
The survival in our study was similar in the two groups of
patients, even in respect to long-term survival. Moreover, the
survival was quite comparable with survival data reported in other
studies of renal cell carcinoma patients treated with IL-2/a-IFN
(e.g. Facendola et al, 1995). In fact, median survival in each of the
treatment arms was better than that seen in Swedish registry
studies. This gives further support that the doses delivered to
patients were of clinical significance. The survival analysis did not
seem to be different regardless of the time frame of the analysis
(from the date of primary diagnosis or the start of the treatment or
from the time of first signs of metastatic spread).
There was no obvious initial variation in laboratory parameters
or metastatic spread of the disease, which further reduces the risk
of differences in prognostic factors between the groups.
Furthermore, there exist several previously published studies that
support our observations (Steineck et al, 1990; Wagstaff et al,
1995; Ljungberg and Henriksson, 1997).
The past decades have without doubt shown an outstanding
increase in the knowledge about tumour immunology and
biotherapy. In renal cell carcinoma, the relatively high response
figures induced by a biotherapy approach have encouraged exten-
sive clinical studies. We would like to stress that we do not deny
the beneficial effects of biotherapy seen by several other authors
(e.g. Atzpodien et al, 1995), and agree that there might exist
subgroup of highly selected patients with renal cell carcinoma that
can really benefit from biotherapy. We also agree that other treat-
ment approaches, like inhalation of IL-2, can be promising.
Therefore, we are eagerly waiting the first reported experiences
from 1989 of local delivery of IL-2 by Huland and co-workers
evaluated in a controlled randomized study.
At present, regardless of our study, there is no standard
immunotherapy (a conclusion made in our study) that can be
recommended since the results obtained do not suggest an obvious
therapeutic benefit for the larger patient population suffering from
advanced renal cell carcinoma. It is obvious that there is much
need for investigation to find the optimal biotherapy schedule, i.e.
a significant increase in survival with an acceptable quality of life.
R Henriksson
Department of Oncology, University Hospital, Umeå, Sweden,
P Wersäll 
Radiumhemmet, Karolinska Institute, Stockholm, Sweden
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Hereditary factors in basal cell carcinoma of the skin: a
population-based cohort study in twins
Sir,
Milan et al (Br J Cancer 1998 78: 1516–1520) reported on a large
twin study investigating the contribution of hereditary factors in
basal cell carcinoma (BCC) in Finland. This twin study based on
12 941 adult twin pairs with 43 years follow-up data concluded
that genetic factors are not necessary to explain the distribution of
BCC in twins. These findings are of major importance; however, a
number of points need to be addressed in the analysis before these
conclusions can be accepted.